Nektar Therapeutics (MEX:NKTR) Other Current Receivables: MXN65 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NKTR Nektar Therapeutics MEX:NKTR
47 GF Score
Price MXN1,584.15
GF Value MXN134.27
! 5 Warning Signs
View Full Analysis

What is Nektar Therapeutics Other Current Receivables?

Nektar Therapeutics MEX:NKTR 47 Other Current Receivables is MXN65 Mil as of Mar. 2026. GuruFocus rates MEX:NKTR with a GF Score™ of 47/100 and a GF Value™ of MXN134.27. The stock has 5 warning signs investors should review.

Nektar Therapeutics's Other Current Receivables for the quarter that ended in Mar. 2026 was MXN65 Mil.

Nektar Therapeutics's quarterly Other Current Receivables increased from Sep. 2025 (MXN23.65 Mil) to Dec. 2025 (MXN32.03 Mil) and increased from Dec. 2025 (MXN32.03 Mil) to Mar. 2026 (MXN64.92 Mil).

Nektar Therapeutics's annual Other Current Receivables increased from Dec. 2023 (MXN17.77 Mil) to Dec. 2024 (MXN33.56 Mil) but then declined from Dec. 2024 (MXN33.56 Mil) to Dec. 2025 (MXN32.03 Mil).

Nektar Therapeutics Other Current Receivables Related Terms

Nektar Therapeutics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Nektar Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics Other Current Receivables Chart

Nektar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 47.24 17.77 33.56 32.03

Nektar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.07 25.44 23.65 32.03 64.92
MEX:NKTR
47GF Score
Nektar Therapeutics MEX:NKTR
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nektar Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of MXN65 Mil mean?
Nektar Therapeutics (MEX:NKTR) has a Other Current Receivables of MXN65 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Nektar Therapeutics and its competitors.
Is Nektar Therapeutics' Other Current Receivables too high?
Nektar Therapeutics' current Other Current Receivables is MXN65 Mil. Overall, Nektar Therapeutics has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' Other Current Receivables compare to OCUL and PVLA?
Nektar Therapeutics' Other Current Receivables of MXN65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Nektar Therapeutics and its competitors. Nektar Therapeutics's current Other Current Receivables is MXN65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Nektar Therapeutics (MEX:NKTR) has a current Other Current Receivables of MXN65 Mil. The stock's GF Value™ is MXN134.27, compared to a current price of MXN1,584.15 — trading 1079.8% above its estimated fair value. The current Other Current Receivables is MXN65 Mil. Nektar Therapeutics' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Nektar Therapeutics (MEX:NKTR), the current Other Current Receivables is MXN65 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nektar Therapeutics (MEX:NKTR) Overvalued in 2026?

Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued. The current stock price of MXN1,584.15 is trading 1079.8% above its estimated GF Value™ of MXN134.27.

Key valuation signals for MEX:NKTR:

  • Other Current Receivables: MXN65 Mil
  • GF Value™: MXN134.27 vs. price of MXN1,584.15 (1079.8% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the MEX:NKTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nektar Therapeutics Business Description

Other Exchanges NKTR:USA0UNL:UKITH0:Germany
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
47GF Score

Get the complete analysis for MEX:NKTR

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,584.15
Price
MXN134.27
GF Value